Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
5 Cell phones of the Year- Giude to Best Web based Learning Stage
- Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- Baidu robotaxi outage in Wuhan caused by 'system failure', police say
- Radiate brilliantly: The 5 Precious stone Rings to Purchase in 2024
- 'We were genuinely astonished': This moss survived 9 months outside the International Space Station and could still grow on Earth
- Vote in favor of your Number one method for praising a birthday
